INTRODUCTION {#s1}
============

Post-transplant lymphoproliferative disorders (PTLD) encompass morphologically heterogeneous entities with variable clinical behavior. \[[@R1]\] PTLDs of B-lineage predominate, while T- and NK-cell PTLDs (T/NK-PTLD) are rare, representing 2-15% of all cases. \[[@R2]\] T/NK-PTLDs usually present late after transplantation, are associated with a poor prognosis, and, in contrast to B-cell PTLDs, only a minority are EBV-related (up to 37%). \[[@R2], [@R3]\]

The pathogenesis of T/NK-PTLDs and the underlying molecular alterations are presently unknown and their relationship to peripheral T-cell lymphomas (PTCL) arising in immunocompetent hosts remains unclear. Hence, in order to gain insights into the genetic bases of these uncommon PTLDs, we performed targeted next generation sequencing of cancer-associated genes and genome-wide DNA profiling to assess copy number alterations in a relatively large series of well characterized T/NK-PTLDs. We observed frequent mutations of epigenetic modifiers, members of the JAK/STAT signaling cascade, and TP53, and recurrent genomic alterations, similar to those described in PTCL arising in immunocompetent individuals.

RESULTS {#s2}
=======

Morphology and immunophenotype {#s2_1}
------------------------------

All T- and NK-cell lymphomas were classified based on morphologic and immunophenotypic features according to the 2008 WHO guidelines. \[[@R4]\] Immunophenotypic analysis was based on a combination of flow cytometry and immunohistochemistry. Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) was the most common subtype (*n* = 6, 32%), followed by hepatosplenic T-cell lymphoma (HSTCL; *n* = 3), primary cutaneous anaplastic large cell lymphoma (c-ALCL; *n* = 3), angioimmunoblastic T-cell lymphoma (AITL; *n* = 2), extranodal NK/T-cell lymphoma, nasal type (ENKTCL; *n* = 2), EBV-positive peripheral T-cell lymphoma (EBV+ PTCL; *n* = 1), lymphomatoid papulosis (LyP; *n* = 1) and adult T-cell leukemia/lymphoma (ATLL; *n* = 1) (Table [1](#T1){ref-type="table"}, representative cases are illustrated in Figure [1](#F1){ref-type="fig"}).

###### Clinical, morphological and immunohistochemical data

  Case   Age/Sex   Underlying dx                   Graft       IS therapy   Time to PTLD (y)   Diagnosis                       Location                    CD2   CD3   CD5   CD7   CD4   CD8   CD56   TIA   CD30   EBER                                    Ki-67   Other                              B-catenin   MLH1   MSH2   PMS2   MSH6   Gata3   Lineage   MSI status   TCR      Treatment                                            Status   Survival (days)
  ------ --------- ------------------------------- ----------- ------------ ------------------ ------------------------------- --------------------------- ----- ----- ----- ----- ----- ----- ------ ----- ------ --------------------------------------- ------- ---------------------------------- ----------- ------ ------ ------ ------ ------- --------- ------------ -------- ---------------------------------------------------- -------- -----------------
  1      75F       Viral CM                        Heart       AZA+CS+P     15.01              PTCL, NOS                       BM                          \+    \-    \+    \-    \-    \+    \-     \+    ND     \-                                      30%                                        ND          ND     ND     ND     ND     ND      ND        MSS          Clonal   VMP                                                  Dead     66
  2      29M       Viral CM                        Heart       AZA+CS+P     12.62              PTCL, NOS                       Subcutaneous tissue, face   \+    \+    \+    \-    \+    \-    \-     ND    \-     \-                                      ND      PD1-                               \-          \+     \+     \+     \-     \-      ND        MSI-H        Clonal   CHOP/RT, gemcitabine                                 Dead     197
  3      57M       Hypersensitivity pneumonitis    Left lung   CNI+MMF+P    0.47               PTCL, NOS                       Subcarinal LN               \+    \+    +/−   −     −     \+    −      \+    −      −                                       80%     CD10-, CD15-, PD1-, CD25-, MUM1-   −           \+     \+     \+     \+     −       αβ        MSS          Clonal   EPOCH                                                Dead     98
  4      75M       Dilated CM                      Heart       CNI+MMF+P    2.00               PTCL, NOS                       Retroperitoneum             \+    \+    +/−   +/−   \+    −     −      −     −      −                                       40%     ALK-, BCL2-, MUM1-, PD1-           ND          ND     ND     ND     ND     ND      ND        ND           Clonal   Cytoxan/Etoposide                                    Dead     29
  5      41F       Post-partum CM                  Heart       CNI+P+MMF    7.01               PTCL, NOS                       Retroperitoneum             \+    \+    \+    −     \+    −     −      −     −      −                                       ND      CD10-, BCL2+, PD1+, MUM1-          −           \+     \+     \+     \+     −       αβ        MSS          PC       EPOCH, GEMOX, Pralatrexate, Radiation and Auto-SCT   Alive    976
  6      32F       CHF                             Heart       CS           14.01              EBV+ PTCL                       Breasts, bilateral          \+    \+    \+    −     +/−   \+    −      \+    \+     \+                                      70%     CD10-, ALK-, MUM1-                 ND          ND     ND     ND     ND     ND      ND        MSS          Clonal   EPOCH, Radiation and gemcitabine                     Alive    1405
  7      32M       N/A                             Liver       CNI+AZA+CS   5.83               HSTCL                           Spleen, liver, BM           \+    \+    −     \+    −     \+    \+     \+    −      −                                       ND                                         −           \+     \+     \+     \+             γδ        MSS          Clonal   VDMCT                                                Dead     120
  8      34M       Dilated CM                      Heart       AZA+CS+P     9.73               HSTCL                           Spleen                      ND    \+    −     −     −     \+    ND     \+    −      −                                       ND                                         −           \+     \+     −      \+     −       γδ        MSS          Clonal   CHOP, ESHAP, MNM                                     Dead     273
  9      35M       GN, NOS                         Kidney      AZA+CS+P     10.01              HSTCL                           Spleen, liver               \+    \+    −     ND    −     −     \+     \+    ND     ND                                      ND      PD1-                               −           −      \+     \+     \+     70%     γδ        MSS          Clonal   CHOP                                                 Dead     70
  10     57F       DM                              Kidney      n/a          24.43              AITL                            Retroperitoneum             \+    \+    \+    −     \+    −     ND     ND    −      −                                       50%     BCL6+, CD10+, PD1+                 −           \+     \+     \+     \+     30%     αβ        MSS          PC       RCHOP/Gemcitabine/Pralatrexate                       Dead     321
  11     44M       N/A                             Lung        CNI+CS       4.08               AITL                            LN, lung                    \+    \+    \+    \+    \+    −     −      ND    −      \-[\*](#tfn_001){ref-type="table-fn"}   ND      BCL6+, PD1+                        ND          \+     \+     \+     \+     ND      ND        MSS          Clonal   Rituximab                                            Dead     730
  12     83M       N/A                             Kidney      CNI+MMF+CS   6.92               Primary cutaneous ALCL, CD30+   Skin, pleura                \+    −     −     −     \+    −     ND     −     \+     −                                       ND      ALK-                               −           \+     \+     \+     \+     ND      ND        MSS          ND       CHOP                                                 Dead     120
  13     47M       Nephrogenic systemic fibrosis   Kidney      CNI+MMF      4.73               Primary cutaneous ALCL, CD30+   Skin, back                  \+    −     −     −     \+    −     ND     −     \+     −                                       80%     ALK-, BCL2+                        −           \+     \+     \+     \+     80%     αβ        MSS          Clonal   CHOP/RT                                              Dead     3839
  14     71M       N/A                             Heart       CNI+AZA+CS   18.00              Primary cutaneous ALCL, CD30+   Skin                        \+    −     −     −     \+    −     ND     −     \+     −                                       ND      ALK-                               ND          ND     ND     ND     ND     ND      ND        ND           Clonal   CHOP                                                 Dead     210
  15     20F       Drug induced CM                 Heart       AZA+CS+P     5.49               ENKTCL                          Right breast                \+    \+    −     \+    −     −     \+     \+    −      \+                                      70%     CD25+                              −           \+     \+     \+     \+     −       \--       MSS          PC       N/A                                                  Dead     18
  16     71F       Hypersensitivity pneumonitis    Lung        CNI+AZA+P    7.40               ENKTCL                          Nasal vestibule, lung       \+    \+    \+    +/−   −     \+    −      \+    −      \+                                      90%                                        ND          ND     ND     ND     ND     ND      αβ        ND           Clonal   None                                                 Dead     61
  17     43F       FSGS                            Kidney      CNI+AZA+P    6.98               ATLL                            Retroperitoneum             \+    −     −     −     \+    −     −      ND    \+     −                                       ND      ALK-, FoxP3-, CD25+, MUM1+         ND          ND     ND     ND     ND     ND      ND        ND           Clonal   EPOCH X4                                             Alive    650
  18     83M       APCKD                           Kidney      CNI+MMF      3.23               Lymphomatoid papulosis          Skin, left forearm          \+    −     −     −     −     −     −      ND    \+     −                                       ND      CD15+, ALK-, MUM1+                 ND          ND     ND     ND     ND     ND      ND        ND           PC       Reduced IS                                           Alive    2741
  19     70M       N/A                             Kidney      CNI+AZA+CS   1.92               PTCL, NOS                       Pleura, pericardium, LN     \+    \+    −     −     \+    −     −      −     −      −                                       ND      ALK-                               ND          ND     ND     ND     ND     ND      ND        MSS          Clonal   None                                                 Dead     60

Immunosuppression; MSI: Microsatellite instability; TCR: T-cell receptor clonality; CM: Cardiomyopathy; CHD: Congestive heart failure; GN: Glomerulonephritis; DM: Diabetes Mellitus; FSGS: Focal segmental glomerulosclerosis; APCKD: Autosomal dominant polycystic kidney disease; LN: Lymph node; BM: Bone marrow; AZA: Azathioprine; CS: Corticosteroids; P: Prednisone; CNI: Calcineurin inhibitor; MMF: Mycophenolate mofetil; RT: Radiotherapy; N/A: Not available; ND: Not done; PC: Polyclonal;

EBER+ B-cells were present

![Histopathologic and phenotypic features of selected subtypes of T/NK-PTLD\
**A.** and **B.** EBV+ PTCL in the breast; CD8+ and EBER+. **C.** and **D.** PTCL, NOS presenting as a retroperitoneal mass; CD4+ and PD1+. **E.** and **F.** Hepatosplenic T-cell lymphoma in the spleen; TCR-gamma+. **G.** and **H.** PTCL, NOS in subcarinal lymph node; CD8+.](oncotarget-07-37636-g001){#F1}

PTCL, NOS (*n* = 6) comprised CD4+ and CD8+ cases with downregulation or loss of CD7 seen in all. One CD8+ T-cell lymphoma expressed CD30 and showed evidence of EBV infection by *in situ* hybridization for EBER. The three cases of HSTCL were derived from TCR-gamma-delta T-cells. They expressed TIA-1 but not the cytotoxic granule constituents (granzyme-B, perforin) and lacked CD5 expression. The AITL cases were CD4+ and displayed expanded and disrupted follicular dendritic cell meshworks. One case had a concomitant EBV+ clonal B-cell proliferation. The c-ALCL cases showed diffuse dermal infiltrates of large CD30+ T-cells, many exhibiting prominent nucleoli, and lacked ALK expression. Both ENKTCL were EBV+. One was of cytotoxic T-cell origin involving the breast and the other of NK-cell origin involving the nasal vestibule and lung; both displayed cellular atypia, had high proliferation indices and showed angiodestruction and extensive necrosis. The ATLL presented as lymphomatous disease and the neoplastic cells expressed CD4 and CD25.

Clinical characteristics {#s2_2}
------------------------

The detailed clinical features of the 19 T/NK-PTLD are described in Table [1](#T1){ref-type="table"}. The median age was 47 (range: 20-83) and 12/19 (63%) patients were male. The most commonly transplanted organ was heart (*n* = 8), followed by kidney (*n* = 7), lung (*n* = 3) and liver (*n* = 1). Immunosuppressive therapy comprised calcineurin inhibitors (*n* = 12), corticosteroids (*n* = 11), azathioprine (*n* = 10), and mycophenolate mofitil (*n* = 6); no association between the type of therapy and organ allograft was observed. The median interval between organ transplantation and diagnosis was 7 years (range: 0.5 - 18 y). Extranodal disease was seen in 15/19 (79%) cases and 3 (16%) cases were EBV+. The types of therapies for PTLD and response to treatment varied. The patient with lymphomatoid papulosis (case 18) was treated with reduction in immunosuppression alone, which led to disease regression. Four patients received a combination of chemotherapy and radiation and 12 received chemotherapy alone. Two patients were referred for palliative care. Clinical remission was achieved in 1 patient with c-ALCL (case 13) who presented with localized disease, after treatment with chemotherapy and radiation; he died of disease unrelated causes 12 years post diagnosis. One patient with EBV+ PTCL (case 6) is in remission 4 years after diagnosis having received chemotherapy with etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) and one individual with PTCL, NOS (case 5) achieved remission after chemotherapy, radiation, and allogeneic stem cell transplantation. The patient diagnosed with ATLL, based on positive serology for HTLV-1, was treated with EPOCH and is alive 2 years after diagnosis. Despite aggressive treatment, however, the median overall survival was 6.6 months (range: 18 days to 12 years).

Genome-wide copy number alterations {#s2_3}
-----------------------------------

Copy number alterations were observed in 12/16 cases (75%; complex = 8, simple = 4). Loss of heterozygosity was noted in 7/16 (44%) cases (Figure [3F](#F3){ref-type="fig"}; Table [2](#T2){ref-type="table"}). No recurrent alterations were seen in 5 cases of PTCL, NOS. Two of three HSTCL showed 7q gain and 7p loss, indicative of isochromosome 7q. One of two ENKTCL showed loss of 6q. Copy number alterations in 1 of 2 cases of c-ALCL analyzed included 1p gain and losses at 13q and 16q. No copy number changes were detected in the ATLL and lymphomatoid papulosis.

###### Genomic alterations in T/NK-PTLDs

  Case   Subtype     Gain/Loss                Locus              Base Positions                  Size (mb)   Total Genes   Genes identified in Cancer Gene Census
  ------ ----------- ------------------------ ------------------ ------------------------------- ----------- ------------- ----------------------------------------------------------------------------------------------------------------------------------------------------
  1      PTCL, NOS   Not analyzed                                                                                          
  2      PTCL, NOS   Loss                     7p22.1p15.3        chr7:6,327,460-23,472,983       17.14Mb     85            1(ETV1)
  3      PTCL, NOS   Gain                     9p24.3p24.1        chr9:681,960-7,237,233          6.5mb       42            2 (JAK2, CD274)
                     Gain                     11q22.3q25         chr11:105,115,252-135,006,516   29.89       304           11 (ATM, DDX10, POU2AF1, SDHD, PAFAH1B2, PCSK7, MLL, DDX6, ARHGEF12, FLI1)
                     Loss                     6q11.1q27          chr6:62,173,195-170,837,508     108.66      561           10 (PRDM1, ROS1, GOPC, STL, MYB, TNFAIP3, ECT2L, EZR, FGFR1OP, MLLT4)
  4      PTCL, NOS   Loss                     20q13.13q13.2      Chr20:48,080,029-51,759119      3.42Mb      33            None
  5      PTCL, NOS   Gain                     4q28.1q34.1        chr4:125,081,373-175,395,062    50.31Mb     180           19(FBXW7)
                     Gain                     14q31.1q32.33      chr14:83,163,335-106,495,970    23.33Mb     294           8 (TRIP11, GOLGA5, DICER1, TCL6, TCL1A, BCL11B, AKT1, IGH)
                     LOH                      10q23.32q25.1      chr10:92,990,108-106,337,119    13.34       196           3 (TLX1, NFKB2, SUFU)
                     Loss                     17p13.3p11.2       chr17:400,959-21,516,719        21.11Mb     419           6 (YWHAE, USP6, TP53, PER1, GAS7, MAP2k4)
  6      EBV+ PTCL   Gain                     2q14.2q37.3        chr2:120,196,122-243,199,373    123.00Mb    803           13(ERCC3, CHN1, HOXD13, HOXD11, NFE2L2, PMS1, SF3B1, CREB1, IDH1, ATIC, FEV, PAX3, ACSL3)
                     Gain                     3p26.1p14.3        chr3:7,153,652-58,391,565       51.23Mb     528           12(SRGAP3, FANCD2, VHL, PPARG, RAF1, XPC, MLH1, MYD88, CTNNB1, SETD2, BAP1, PBRM1)
                     Loss                     6q11.2q24.2        chr6:57,730,420-143,488,404     85.75Mb     370           7(PRDM1, ROS1, GOPC, STL, MYB, TNFAIP3, ECT2L)
                     LOH                      17q21.2q25.3       chr17:40,324,798-80,263,427     39.93Mb     678           14(BRCA1, ETV4, COL1A1, HLF, MSI2, CLTC, BRIP1, CD79B, DDX5, PRKAR1A, SRSF2, CANT1, ASPSC, STAT3)
                     LOH                      9q33.3q34.13       chr9:126,794,173-135,302,624    8.5         144           4 (SET, FNBP1, ABL1, NUP214)
                     LOH                      15q23q25.1         chr15:71,689,059-79,548,077     7.85        121           1 (PML)
                     Loss                     Xp22.33q28         chrX:177,942-155,219,364        155.04Mb    1285          CRLF2, P2RY8, ZRSR2, BCOR, KDM6A, SSX1, WAS, GATA1, TFE3, SSX2, KDM5C, MSN, MED12, NONO, ATRX, SEPT6, ELF4, GPC3, PHF6, MTCP1)
  7      HSTCL       Gain                     1q21.3 - q25.2     chr1:154,087,033-176,562,796    22.47576    369           7 (TPM3, MUC1, PRCC, NTRK1, SDHC, FCGR2B, PBX1)
                     Loss                     4p15.32 - p15.2    chr4:16,152,859-25,102,176      8.949318    29            None
                     Loss                     4q13.1 - q23       chr4:62,726,234-100,740,709     38.01448    230           1 (RAP1GDS1)
                     Loss                     7p22.2 - p11.1     chr7:3,896,634-61,064,518       57.16789    373           9 (PMS2, ETV1, HNRNPA2B1, HOXA9, HOXA11, HOXA13, JAZF1, IKZF1, EGFR)
                     Gain                     7q11.22 - q21.11   chr7:70,468,676-77,724,388      7.255713    103           2 (ELN, HIP1)
                     LOH                      7q31.1 - q36.3     chr7:110,440,775-159,118,443    48.7        401           7 (MET, SMO, CREB3L2, KIAA1549, BRAF, EZH2, MLL3)
                     Gain                     8q11.21 - q24.3    chr8:51,192,818-146,364,002     95.2        571           10 (TCEA1, PLAG1, CHCHD7, NCOA2, HEY1, COX6C, EXT1, MYC, NDRG1, RECQL4)
                     LOH                      11q13.3q25         chr11:70,834,389-135,006,516    64.2        559           15 (NUMA1, PICALM, MAML2, BIRC3, ATM, DDX10, POU2AF1, SDHD, PAFAH1B2, PCSK7, MLL, DDX6, CBL, ARHGEF12, FLI1)
                     Gain                     17q21.31-q25.3     chr17:41,516,675-80,366,217     16.8        634           12 (ETV4, COL1A1, HLF, MSI2, CLTC, BRIP1, CD79B, DDX5, PRKAR1A, SRSF2, CANT1, ASPS)
                     Gain                     22q12.3 - q13.33   chr22:32,252,434-51,304,566     19.1        302           4 (MYH9, PDGFB, MKL1, EP300)
                     Homozygous loss          Yp11.31 - q11.23   chrY:2,660,163-28,799,935       26.1        189           None
  8      HSTCL       Loss                     7p22.3p11.2        chr7:41,421-55,272,715          55.23Mb     396           8(CARD11, PMS2, ETV1, HNRNPA2B1, HOXA9, HOXA11, HOXA13, JAZF1, IKZF1, EGFR)
                     Gain                     7q11.21q36.3       chr7:61,816,116-159,118,443     97.3        838           12(SBDS, ELN, HIP1, AKAP9, CDK6, MET, SMO, CREB3L2, KIAA1549, BRAF, EZH2, MLL3)
  9      HSTCL       No changes identified.                                                                                
  10     AITL        Loss                     1p31.3 - p31.1     chr1:66,994,889-80,226,910      13.2        72            1 (FUBP1)
                     Loss                     1p13.3 - p11.2     chr1:109,527,108-121,350,934    11.0        151           5 (RBM15, TRIM33, NRAS, FAM46C, NOTCH2)
                     Loss                     2q11.1 - q14.1     chr2:95,439,005-116,163,121     20.7        210           2 (TTL, PAX8)
                     Loss                     2q14.1 - q23.1     chr2:117,810,213-149,194,919    31.4        138           1 (ERCC3)
                     LOH                      4p16.3 - q35.2     chr4:71,566-190,915,650         190.8       1034          13 (FGFR3, WHSC1, SLC34A2, PHOX2B, FIP1L1, PDGFRA, CHIC2, KIT, KDR, RAP1GDS1, TET2, IL2, FBXW7)
                     Gain                     5q31.1 - q31.2     chr5:130,788,642-138,657,896    7.9         102           None
                     Loss                     5q31.2 - q32       chr5:138,689,223-149,136,632    10.4        165           None
                     Loss                     5q33.3 - q34       chr5:157,096,900-160,315,446    3.2         25            1 (EBF1)
                     Gain                     5q35.1 - q35.2     chr5:170,275,961-172,901,400    2.6         24            3 (RANBP17, TLX3, NPM1)
                     Gain                     6p25.3 - p25.1     chr6:204,909-5,172,009          5.0         48            1 (IRF4)
                     LOH                      6p25.3 - p21.1     chr6:5211336-45699405           40.5        628           10 (DEK, HIST1H4I, TRIM27, POU5F1, DAXX, HMGA1, FANCE, PIM1, TFEB, CCND3)
                     Gain                     7p22.3 - p15.3     chr7:41,421-22,798,650          22.8        159           3 (CARD11, PMS2, ETV1)
                     Gain                     7q21.11 - q31.31   chr7:80,054,945-119,098,598     39.0        317           3 (AKAP9, CDK6, MET)
                     Gain                     7q36.2 - q36.3     chr7:154,693,849-157,479,833    2.8         26            None
                     Loss                     8p23.3 - p23.1     chr8:172,417-7,004,147          6.8         47            None
                     Gain                     8q22.2 - q24.11    chr8:99,374,877-117,703,509     18.3        66            1 (COX6C)
                     Gain                     9q21.11 - q34.3    chr9:71,043,202-141118911       70.1        730           15 (GNAQ, SYK, OMD, FANCC, XPA, NR4A3, TAL2, SET, FNBP1, ABL1, NUP214, TSC1, RALGDS, BRD3, NOTCH1)
                     Gain                     11q13.4 - q25      chr11:71,703,483-134,938,847    63.2        543           15 (NUMA1, PICALM, MAML2, BIRC3, ATM, DDX10, POU2AF1, SDHD, PAFAH1B2, PCSK7, MLL, DDX6, CBL, ARHGEF12, FLI1)
                     LOH                      16p13.3 - p13.2    chr16:83,887-8,065,382          8.0         235           2 (TSC2, CREBBP)
                     LOH                      17p13.3 - p11.2    chr17:400,959-16,277,578        15.9        319           6 (YWHAE, USP6, TP53, PER1, GAS7, MAP2K4)
                     Loss                     17q24.3 - q25.3    chr17:67,876,646-76,799,898     8.6         145           1 (SRSF2)
                     Loss                     17q25.3            chr17:79,372,489-80,263,427     0.9         44            1 (ASPSCR1)
                     Gain                     22q12.1 - q12.3    chr22:27,148,121-35,540,423     8.4         100           4 (MN1, CHEK2, EWSR1, NF2)
                     Gain                     Xp22.33            chrX:177,942-2,000,942          1.8         15            2 (CRLF2, P2RY8)
                     Loss                     Xp22.2             chrX:10,983,386-12,957,293      2.0         9             None
                     LOH                      Xp22.33 - p11.1    chrX:177,942-155,219,364        155.0       1286          21 (CRLF2, P2RY8, ZRSR2, BCOR, KDM6A, SSX1, SSX4, WAS, GATA1, TFE3, SSX2, KDM5C, MSN, MED12, NONO, ATRX, SEPT6, ELF4, GPC3, PHF6, MTCP1)
                     Loss                     Xp21.3 - p11.3     chrX:28,468,750-43,844,600      15.4        57            1 (BCOR)
                     Gain                     Xp11.3 - p11.22    chrX:43,851,171-53,446,146      9.6         221           8 (KDM6A, SSX1, SSX4, WAS, GATA1, TFE3, SSX2, KDM5C)
                     Loss                     Xq21.31 - q22.3    chrX:90,213,826-105,763,052     15.5        90            None
                     Loss                     Xq23 - q25         chrX:112,406,196-121,321,850    8.9         162           1 (SEPT6)
                     Loss                     Xq27.3 - q28       chrX:143,811,457-155,219,364    11.4        209           1 (MTCP1)
  11     AITL        No changes identified.                                                                                
  12     c-ALCL      Gain                     6q21-q24.1         chr6:109,262,907-142,278,857    33.0        30            2 (ROS1, GOPC)
                     LOH                      17p13.3-12         chr17:1-15,645,289              15.6        315           6 (YWHAE, USP6, TP53, PER1, GAS7, MAP2K)
  13     c-ALCL      Gain                     1p36.22p36.21      chr1:9,744,244-13,187,252       3.44Mb      72            None
                     Gain                     10p15.3p12.2       chr10:126,070-23,745,727        23.61Mb     160           2(GATA3, MLLT10)
                     Loss                     13q13.1q34         chr13:32,540,047-115,103,150    82.56Mb     438           5(BRCA2, LHFP, LCP1, RB1, ERCC5)
                     Loss                     16q12.1q23.2       chr16:49,691,925-80,146,038     30.45Mb     303           6 (CYLD, HERPUD1, CDH11, CBFB, CDH1, MAF)
                     Loss                     16q23.3q24.1       chr16:82,431,694-86,293,870     3.86Mb      41            None
  14     c-ALCL      Not analyzed                                                                                          
  15     ENKTCL      Gain                     2q24.3q32.3        chr2:164,197,701-195,534,597    31.33 Mb    183           5 (CHN1, HOXD13, HOXD11, NFE2l2, PMS1)
                     LOH                      2q33.1-q37.3       chr2:198,858,917-243,052,331    44.19Mb     401           6 (CREB1, IDH1, ATIC, FEV, PAX3, ACSL3)
                     Loss                     3p13p12.3          chr3:69,852,242-79,214,617      9.36        29            2(MITF, FOXP1)
                     Loss                     4q32.3q35.2        chr4:166,281,785-190,915,650    24.6        98            None
                     Gain                     5q21.3q35.3        chr5:105,294,321-180,698,312    75.4        62            9 (APC, PDGFRB, CD74, ITK, EBF1, RANBP17, TLX3, NPM1, NSD1)
                     Gain                     6p25.3p24.3        chr6:204,909-9,047,746          8.84Mb      67            1 (IRF4)
                     Loss                     6q16.3q23.3        chr6:101,280,508-138,764,089    37.43       204           None
                     Gain                     9q13q34.12         chr9:68,170,421-133,962,930     65.79       559           10 (GNAQ, SYK, OMD, FANCC, XPA, NR4A3, TAL2, SET, FNBP1, ABL1)
                     Loss                     12q24.33           132,663,422-133,818,115         1.15kb      23            None
                     Loss                     15q24.1q26.2       chr15:73,313,691-97,999,066     24.68Mb     281           5(PML, NTRK3, IDH2, CRTC3, BLM)
                     Loss                     17p13.3p11.2       chr17:400,959-20,301,297        19.90Mb     403           7 (YWHAE, USP6, TP53, PER1, GAS7, MAP2K4, STAT3)
                     Loss                     17q24.1q24.2       chr17:62,680,553-64,867,456     2.1Mb       179           None
                     Loss                     17q11.2q25.3       Chr17:25,899,925-79,934,193     54.09Mb     1034          21 (NF1, SUZ12, TAF15, MLLT6, LASP1, CDK12, ERBB2, RARA, BRCA1, ETV4, COL1A1, HLF, MSI2, CLTC, BRIP1, CD79B, DDX5, PRKAR1A, SRSF2, CANT1, ASPSCR1)
                     Loss                     18p11.32q23        Chr18:128,557-77,991,543        77.86Mb     382           4 (ZNF521, SS18, MALT1, BCL2)
                     Loss                     19p13.3            chr19:247,232-2,303,276         2.0MB       92            3(FSTL3, STK11, TCF3)
                     Gain                     Xq27.3q28          chrX:146,155,369-155,219,364    9.06Mb      195           1(MTCP1)
  16     ENKTCL      Not analyzed                                                                                          
  17     ATLL        No changes identified.                                                                                
  18     LYP         No changes identified.                                                                                
  19     PTCL, NOS   Gain                     1q21.1 - q32.1     chr1:144,940,761-206,669,136    61.7        859           15 (PDE4DIP, BCL9, ARNT, TPM3, MUC1, PRCC, NTRK1, SDHC, FCGR2B, PBX1, ABL2, TPR, MDM4, ELK4, SLC45A3)
                     LOH                      3p26.3 - p21.1     chr3:63,411-52,826,707          52.8        510           12 (SRGAP3, FANCD2, VHL, PPARG, RAF1, XPC, MLH1, MYD88, CTNNB1, SETD2, BAP1, PBRM1)
                     Loss                     7p22.3 - p11.2     chr7:1-57,754,465               58.0        422           10 (CARD11, PMS2, ETV1, HNRNPA2B1, HOXA9, HOXA11, HOXA13, JAZF1, IKZF1, EGFR)
                     Gain                     7q11.21-q34        chr7:62827731-142378708         79.6        658           10 (SBDS, ELN, HIP1, AKAP9, CDK6, MET, SMO, CREB3L2, KIAA1549, BRAF)
                     Gain                     8p23.3q24.3        chr8:172,417-146,292,734        146.1       966           15 (WHSC1L1, FGFR1, HOOK3, TCEA1, PLAG1, CHCHD7, PCM1, WRN, NCOA2, HEY1, COX6C, EXT1, MYC, NDRG1, RECQL4)

LOH: Loss of heterozygosity

Targeted next generation sequencing {#s2_4}
-----------------------------------

Somatic mutations were detected in 17/18 cases (94%) using targeted sequencing of 465 cancer associated genes. Overall, 377 variants were identified: 286 missense (76%), 31 indels (8%), 16 nonsense (4%), and 44 intronic (12%) ([Suppl. Table 1](#SD2){ref-type="supplementary-material"}), with an average of 594.8-fold coverage and \> 10X coverage for 99% of the coding regions ([Suppl. Table 2](#SD3){ref-type="supplementary-material"}). The pathogenic variants, focusing on genes recurrently targeted or implicated in hematologic malignancies, are listed in Figure [2](#F2){ref-type="fig"}.

Heterozygous mutations of epigenetic modifier genes were the most frequently observed alterations (11/18, 61%). *TET2* mutations were seen in four cases; missense (*n* = 2, including R1359G), frameshift (*n* = 1), and nonsense accompanied by LOH of 4q24 (*n* = 1, R544X). Mutations in histone and DNA methyltransferases (*KMT2D*, *KMT2C, DNMT3A*) and the histone demethylase (*KDM6B*) occurred in 7/18 (39%) cases. Missense and frameshift mutations in chromatin remodeling complex genes (*ARID1B*, *ARID2*) were seen in 5 (28%) cases.

Disruption of *TP53* was identified in 6 of 18 (33%) cases (Figure [3A, 3B](#F3){ref-type="fig"}). Biallelic inactivation was noted in 3 cases (co-occurrence of mutation with 17p LOH) and monoallelic missense mutations in two cases. All missense mutations (*n* = 4) are classified as non-functional or partially functional in the IARC *TP53* database (Version R17). \[[@R5]\] Deletion of 17p encompassing the *TP53* locus alone was seen in one case.

Alterations of JAK/STAT pathway genes were seen in 5 of 18 cases (28%). *STAT3* and *STAT5B* mutations were mutually exclusive (Figure [3C-3E](#F3){ref-type="fig"}). STAT5B mutations were present in one case each of HSTCL and PTCL, NOS. *STAT3* mutations were present in one case each of c-ALCL, ENKTCL, and the EBV+ PTCL. LOH of the STAT3 locus on 17q was observed in the two EBV+ PTLDs with *STAT3* mutations (EBV+ PTCL and ENKTCL), suggesting biallelic gain of function. These two cases also had loss of 6q encompassing *FOXO3*, *PRDM1* and *PTPRK*. A *JAK3* variant (S568P) adjacent to a previously described hotspot was also present in the *STAT3*-mutated EBV+ PTCL. \[[@R6]\]

Subtype-specific genetic alterations were also identified. One of the two cases of angioimmunoblastic T-cell lymphoma demonstrated known pathogenic mutations in *RHOA* and *FYN,* proteins involved in T-cell motility and proliferation and TCR signaling. \[[@R7]\]

Importantly, mutations in genes not previously implicated in PTCL pathogenesis were also observed. Missense mutations in *MED12* were seen in 3 cases (1 PTCL, NOS and 2 HSTCL), including two novel and potentially damaging variants (R516H and R816Q) and one exon 2 mutation (L36P). Alterations of *TBX3* were observed in 3 of 5 PTCL, NOS. A missense mutation in *MTOR* (W1456L) involving the FAT domain was observed in the EBV+ PTCL. A three base pair insertion mutation was observed in *FBXW7* in one PTCL, NOS, which was confirmed by Sanger sequencing ([Suppl. Figure 1](#SD1){ref-type="supplementary-material"}).

![Selected mutations identified by next-generation sequencing in 18 cases of T/NK-PTLD\
Total number of subjects with mutations is listed at right. A green box indicates mutation co-occurring with genomic loss or LOH, yellow box indicates MSI-H status as a consequence of mutation and grey columns indicate 3 EBV+ PTLD.](oncotarget-07-37636-g002){#F2}

Microsatellite instability {#s2_5}
--------------------------

Variants in mismatch repair (MMR) genes were detected in 4 of 18 PTLD (cases 1, 2, 8, and 15, Figure [2](#F2){ref-type="fig"}). However only one (6%) PTLD (case 2) with a heterozygous *PMS2* mutation and PMS2 loss by immunohistochemistry showed evidence of high level microsatellite instability (MSI-H); alterations at 5/5 mononucleotide repeats accounting for 7% (1/14) of all cases analyzed with a panel of microsatellite markers. The remaining 3 cases showed normal immunohistochemical expression of the MMR gene products.

![Schematic representation of the types and locations of *TP53, STAT3* and *STAT5b* mutations\
**A.** *TP53* mutations. **B.** Table showing T/NK-PTLD subtypes with *TP53* mutation and 17p copy number changes. **C.** *STAT3* mutations in the SH2 domain. **D.** *STAT5b* mutations in the SH2 domain. **E.** Table showing T/NK-PTLD subtypes with *STAT3* or *5b* mutations, and 17q copy number changes. **F.** Ideogram of copy number changes detected in 16 cases of T/NK-PTLD. Gains are indicated in blue, losses in red and LOH in green.](oncotarget-07-37636-g003){#F3}

DISCUSSION {#s3}
==========

Our series of T/NK-PTLD comprised a spectrum of PTCL subtypes that have been reported to occur post organ transplantation and are recognized as monomorphic PTLDs in the 2008 WHO classification \[[@R3], [@R4]\]. Epidemiologic data drawn from national registries have shown a higher frequency of PTCL, NOS, ALCL, HSTCL, and ENKTCL in transplant recipients. \[[@R8]\] Data regarding other PTCL subtypes in the setting of immunosuppression (e.g. AITL, ATLL) are limited. \[[@R9], [@R10]\] Cases of ATLL, however, have been reported in recipients of solid organ allografts in multiple series. \[[@R11], [@R12]\] In fact, immunosuppression has been proposed as a risk factor for neoplastic transformation in HTLV-1 carriers post organ transplantation. \[[@R13]\] Our observations support the broad definition of T/NK-PTLD in the current WHO classification and suggest inclusion of more detailed phenotypic information in PTLD databases, which will allow precise classification of PTCL and help determine the role of immune deregulation in the pathogenesis of different disease subtypes.

The clinicopathological features of T/NK-PTLD are distinct from B-cell PTLDs. In contrast to B-cell PTLDs, which are EBV-driven in 55-65% of cases, only 3 of 19 (16%) T/NK-PTLD in our series showed evidence of EBV infection. \[[@R14]\] Consistent with prior reports, disease presentation was late after transplant, with a median of 7 years between onset of immunosuppression and the development of lymphoma. The time of occurrence of B-cell PTLDs has an apparent bimodal distribution with the largest peak occurring in the first year after transplantation and a smaller peak observed five years after transplantation. \[[@R8]\] While a subset of B-cell PTLDs respond to reduction in immunosuppression, the majority of the T/NK-cell PTLDs do not, and they are associated with poor outcomes despite aggressive treatment. \[[@R15]\] Disease biology, however, appears to mirror the subtype specific differences observed in T-cell lymphomas of immunocompetent individuals. Lymphomatoid papulosis followed a fairly indolent course with survival over 10 years, while ENKTCL and HSTCL were rapidly fatal.

The genomic alterations detected in our cohort were similar to those described in PTCLs occurring in immunocompetent hosts. \[[@R16], [@R17]\] Changes consistent with isochromosome 7q, a characteristic feature of HSTCL, were identified in 2 cases of HSTCL. Loss of 13q, encompassing *ING1* and 16q, encompassing the *CTCF* locus, seen in one c-ALCL, have been reported in non-transplant associated c-ALCL. \[[@R18]\] One of two ENKTCL and the EBV+ PTCL showed loss of 6q. This recurrent abnormality, which is observed in 29-52% of ENKTCL arising in immunocompetent individuals, encompasses loci of the *FOXO3* and *PRDM1* genes, which have been shown to function as tumor suppressors in ENKTCL and subtypes of PTCL. \[[@R16], [@R19], [@R20]\] In contrast to EBV+ B-PTLD, however, we observed a higher frequency of complex copy number changes in EBV+ T-PTLD. \[[@R21]\]

Mutations of epigenetic modifier genes were the most frequent alterations (61%) in T/NK-PTLD and were most commonly observed in cases of PTCL, NOS and AITL. A similar mutational spectrum is frequently observed in PTCL occurring in immunocompetent individuals. \[[@R7], [@R22], [@R23]\] Loss of function mutations in *KMT2D*/*MLL2*, a lysine specific histone methyltransferase targeting H3K4 residues that is considered to function as a tumor suppressor, have been reported in PTCL arising in immunocompetent individuals and were seen in a variety of T/NK-PTLD. \[[@R24]\] Missense mutations in *TET2*, a methylcytosine dioxygenase that plays an important role in active DNA demethylation, are frequent in both PTCL, NOS and AITL (38% and 33-76%, respectively). \[[@R23], [@R25], [@R26]\] Loss of function mutations in *DNMT3A*, a DNA methyltransferase that is required for genome-wide de novo methylation, are frequent in a variety of malignancies and have been reported in up to 38% of PTCL, NOS and 33%-37% AITL. \[[@R23], [@R26], [@R27]\] In a murine model, the combination of *TET2* loss and *DNMT3A* mutation appeared to cooperate in the development of T-cell lymphomas exhibiting features of AITL. \[[@R28]\] Similar to observations in PTCL, NOS and AITL occurring in immunocompetent individuals, concomitant *TET2* and *DNMT3A* mutations were noted in two cases of PTCL, NOS in our series. \[[@R29]\] Mutations in chromatin modifier genes, including *ARID1B*, and *ARID2*, were also common, a finding in line with prior studies of PTCL occurring in immunocompetent hosts. \[[@R24]\]

The TP53 pathway is frequently dysregulated in a variety of neoplasms, most commonly by *TP53* mutation or loss, and these lesions are associated with aggressive disease. \[[@R30]\] *TP53* abnormalities are known recurrent changes in a variety of PTCL, albeit at a low frequency (8-9%) and their prognostic significance is unclear in these neoplasms. \[[@R31]--[@R33]\] The higher frequency of *TP53* aberrations in our series (33%) could reflect the small sample size and future larger studies are warranted to determine if the frequency of this genetic lesion is higher in PTCL arising in states of immune dysregulation.

Alterations of the JAK/STAT pathway are frequent in diverse subtypes of PTCL of immunocompetent hosts, including ALCL, HSTCL, T-PLL, ENKTCL, and also in LGL. \[[@R6], [@R34]--[@R37]\] Genetic aberrations activating the JAK-STAT pathway were identified in 28% of T/NK-PTLD, including PTCL, NOS, HSTCL, c-ALCL, and ENKTCL, and an EBV+ PTCL. As previously observed in PTCL, *STAT3* and *STAT5b* alterations were mutually exclusive in T/NK-cell PTLD as well. \[[@R38]\] We observed an association between EBV infection and STAT3 activation. *STAT3* mutations and LOH of the *STAT3* locus were seen in 2 of 3 EBV+ T/NK-PTLDs with concomitant loss of 6q encompassing *PTPRK.* Loss of PTPRK has been associated with constitutive STAT3 activation in ENKTCL. \[[@R39]\] Activation of STAT3 by EBV, even in the absence of genetic lesions, has been shown to induce lymphoproliferative disorders of T- and NK-cells. \[[@R40]\] EBNA-2 is a coactivator of *STAT3* transcription and LMP1 is known to constitutively activate STAT3 in B-cells. \[[@R41], [@R42]\] Of interest, IFN-gamma induced by LMP1 has been shown to enhance STAT1 expression in EBV+ B-PTLD. \[[@R43]\] Whether analogous mechanisms are operational in EBV-associated T/NK-PTLD is not yet known. Nonetheless, our findings suggest that targeting the JAK-STAT pathway with currently available drugs or more selective agents might be of therapeutic benefit in a subset of T/NK-PTLD.

Mutations in genes not previously described in PTCL were also observed. Novel and potentially damaging variants in *MED12* were observed in two cases and a *MED12* exon 2 mutation (L36P), recently described in chronic lymphocytic leukemia, was seen in one case. \[[@R44]\] MED12 is part of the CDK8 subcomplex, which includes CDK8 kinase and cyclin C, of Mediator, a component of the preinitiation complex, with integral roles in transcriptional regulation. \[[@R45]\] The MED12 protein has been shown to regulate JAK/STAT signaling in mouse embryonic fibroblasts \[[@R46]\]. The role of MED12 in normal and neoplastic T-cells, however, is unclear. The functional consequence of mutations of the transcription factor T-box 3 (*TBX3*), a transcriptional repressor, important for myriad developmental processes, \[[@R47]\] noted in three cases, is also not known at present. A novel missense mutation in *MTOR* was detected in an EBV+ PTCL. Similar mutations, which have been shown to activate both mTORC1 and 2 signaling in other neoplasms, may contribute to T-cell growth, survival and proliferation, in part by metabolic reprogramming of lymphocytes. \[[@R48]\] Activation of the mTOR pathway has been reported in T-cell lymphomas, but the presence of mTOR mutations has not been systematically investigated in these malignancies. Of interest, rapamycin analogues, which disrupt the mTORC signaling cascade have shown promise in early phase clinical trials of PTCL patients. \[[@R49]--[@R51]\]

Azathioprine use has been associated with an increased risk of hematological malignancies in allograft recipients and individuals with autoimmune diseases. \[[@R52]\] Thiopurines have been implicated in MMR pathway defects possibly due to epigenetic silencing of the MMR enzymes. \[[@R53]\] Borie et al. reported microsatellite instability (MSI-H) in 9% of immunosuppression-related lymphomas, including 33% (6/18 cases) of PTCL post solid organ transplantation. \[[@R52]\] Only 1 of 10 patients in our series treated with an azathioprine-based immunosuppressive regimen developed a MSI-H tumor. Although the observed frequency of MSI-H was lower in our series (1/14 cases; 7%) than a prior study, this difference was not statisically significant (*p* = 0.1).

In summary, our study represents the first survey of the genetic landscape of T/NK-PTLDs and adds to the growing list of genes altered in T-cell neoplasms that affect a variety of T-cell functions, including activation, proliferation, epigenetic regulation and metabolism. The observed clinicopathologic features and genetic aberrations appear similar to those reported for PTCL subtypes occurring in "immunocompetent" individuals, suggesting shared pathogenetic mechanisms. Our findings raise the possibility of novel therapeutic options for these aggressive lymphomas that need to be explored further in pre-clinical studies.

MATERIALS AND METHODS {#s4}
=====================

Case selection {#s4_1}
--------------

The archives of the Departments of Pathology, Columbia University Medical Center, New York and University Hospitals of KU, Leuven were searched for cases of T/NK-PTLD. Nineteen cases were identified (Columbia University Medical Center, *n* = 14; University Hospitals of KU, Leuven, *n* = 5) that had adequate formalin-fixed, paraffin-embedded (FFPE) tissue for analysis (\> 50% tumor, except for one case of lymphomatoid papulosis with a tumor burden of 20%). We defined T/NK-PTLD as T- or NK-cell lymphomas occurring in individuals after organ transplantation, in accordance with the WHO 2008 guidelines. Morphologic and phenotypic data were reviewed and the lymphomas were classified according to current WHO criteria. \[[@R1]\] Patient demographic and clinical data were collected from the electronic medical record. This study was approved by the Institutional Review Board of Columbia University and performed in accordance with the Declaration of Helsinki.

Whole genome copy number and LOH analysis {#s4_2}
-----------------------------------------

Genome-wide copy number and LOH analysis was performed for 16 cases using the Affymetrix OncoScan FFPE assay (Affymetrix, CA, USA). Briefly, the Oncoscan assay has been optimized to work with DNA from FFPE tissue, utilizing molecular inversion probes to identify changes in copy number and loss of heterozygosity. \[[@R54]\] DNA extraction, sample preparation, hybridization, and scanning were performed according to the manufacturer\'s specifications. Analysis was performed using the Affymetrix Chromosome Analysis Suite 2.0 (ChAS) and Nexus Copy Number 7.5 software (Biodiscovery, Inc. CA, USA).

All copy number alterations and regions of LOH called by the software were verified manually to determine erroneous calls and identify clonal gains and losses undetected by the software(s). Analysis was restricted to gains and losses \> 1 Mb in length. Genomic alterations are reported based on the NCBI build 37 (hg19) of the human genome and cancer-associated genes were curated from the Cancer Gene Census (COSMIC v61 Release;<http://www.sanger.ac.uk/genetics/CGP/Census/>).

Next generation sequencing analysis {#s4_3}
-----------------------------------

Targeted next generation sequencing of 18 tumors and 9 matched normal samples was performed using a panel comprising 465 cancer-associated genes ([Suppl. Table 3](#SD4){ref-type="supplementary-material"}). Fifty to 250 ng of DNA, extracted using the Qiamp mini kit or the Qiamp FFPE kit (Qiagen, Germantown, USA) was fragmented to a median of 150-200bp, by sonication. Following end-repair and 3′ adenylation of the fragments, and ligation of double-stranded sequencing and indexing adaptors to both ends, target capture and enrichment was performed with the Sure Select Hybrid Capture system (Agilent Technologies, Santa Clara, USA), using custom designed probes. Libraries were then quantified using qPCR, diluted to 2nM and pooled, prior to cluster generation and analysis on Illumina HiSeq2500, using Illumina TruSeq v3 chemistry (San Diego, USA) and 100bp paired-end reads (up to 9 indexed samples per run). Fastq files (more than 70% of reads with \> Q30) were demultiplexed with CASAVA, and samples with at least 6Gb of sequencing data were used for mapping and variant calling using NextGene Software (Softgenetics, State College, USA). Reads were aligned to the hg19 (GRCh37) reference genome. At least 3 variant reads were required to call a variant. All calls with ambiguous alignments were excluded, including calls corresponding to regions with large indels. Candidate variants at very low allele frequency (\< 10% of variant reads) were eliminated.

After annotation, the variants were cross referenced with those in the 1000 Genomes Project, OMIM, dbSNP, and the Exome Variant Server. Variants with an allele prevalence \> 1% in the 1000 genomes project were excluded. Common variants present in our departmental database of variants identified in prior constitutional exome analysis, non-pathogenic variants reported in dbSNP, and low quality calls were filtered out. The remaining variants were submitted for manual curation and variant prioritization with visual review of alignments. Synonymous variants and intronic variants greater than 2 bp from the coding sequence were excluded. Variants were manually cross-referenced with the Catalog of Somatic Variants in Cancer (COSMIC) and those that were not known "hot spot" mutations or had not been previously reported as potential driver variants were analyzed by PROVEAN and SIFT algorithms. For cases with matched normal specimens, variants present in the normal samples were excluded.

Assessment of microsatellite instability {#s4_4}
----------------------------------------

Microsatellite instability (MSI) testing was performed in 14 cases using a fluorescent PCR-based assay (MSI Analysis system, Version 1.2, Promega, Madison, WI). Briefly, this test assessed 5 mononucleotide repeats (BAT25, BAT26, NR-21, NR-24, and MONO-27) and 2 pentanucleotide repeats (PentaC and PentaD) on genomic DNA and matched normal, where available. The fluorescently labeled PCR products were analyzed by capillary gel electrophoresis. MSI was determined if the tumor alleles showed a size difference ≥3 bp. Tumors with 2 or more microsatellite unstable markers were classified as MSI-H; the remainder were classified as microsatellite stable (MSS). Immunohistochemistry was performed for MLH1 (clone M1, predilute, Ventana), MSH6 (clone 44, predilute, Ventana), MSH2 (clone G219-1129, predilute, Cell Marque) and PMS2 (clone EPR3947, predilute, Cell Marque) using an autostainer (Benchmark Ultra^TM^ Ventana, Tuscon, AZ) after heat induced antigen retrieval (EDTA, pH 7.3). The ultraView^TM^ Universal DAB Detection kit (Ventana) was used for visualization. Absence of nuclear staining was evaluated in lesional tissue; adjacent stromal cells were used as an internal control.

Methods for DNA extraction, immunohistochemistry, flow cytometry, and Sanger sequencing are described in the [supplemental methods](#SD1){ref-type="supplementary-material"}.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
==========================================
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